AngioDynamics, Inc. (NASDAQ:ANGO) Reports Fiscal Q3 2026 Earnings: Revenue Beats Estimates Despite EPS Miss

• Revenue Growth: AngioDynamics reported $78.4 million in net sales for the third quarter of fiscal 2026, representing an 8.9% year-over-year increase on a pro forma basis and surpassing the consensus estimate of approximately $76.8 million.
• Segment Performance: The Medical Technology segment delivered strong growth with net sales of $37.3 million, up 19% year-over-year. The Medical Device segment contributed $41.1 million, up 1.1%.
• Financial Resilience: The company posted a GAAP net loss of $8.1 million (EPS of -$0.19, missing estimates of -$0.11), but generated adjusted EBITDA of $1.8 million. It maintained a solid balance sheet with $37.8 million in cash and zero debt.

AngioDynamics, Inc. (NASDAQ:ANGO) is a leading medical technology company focused on restoring healthy blood flow in the vascular system, expanding cancer treatment options (including through its NanoKnife platform), and improving patient quality of life. The company operates in two primary segments: Medical Technology (including Auryon atherectomy, AlphaVac thrombectomy, and NanoKnife) and Medical Devices.

On April 2, 2026, AngioDynamics reported its fiscal third-quarter 2026 results (ended February 28, 2026). The company recorded net sales of $78.4 million, up 8.9% year-over-year on a pro forma basis (excluding impacts from previously divested businesses such as the Dialysis and BioSentry product lines). This performance exceeded the Zacks Consensus Estimate and marked another quarter of sustained growth driven by the higher-margin Medical Technology portfolio.

Segment Highlights:

• Medical Technology: Net sales reached $37.3 million, a robust 19% increase year-over-year. This segment now accounts for nearly 48% of total sales and continues its streak of double-digit growth, fueled by strong demand for platforms like Auryon, AlphaVac, and NanoKnife.
• Medical Device: Net sales were $41.1 million, up 1.1% year-over-year.

AngioDynamics reported a GAAP gross margin of 52.9% (down slightly year-over-year due to tariff impacts and manufacturing transitions), generating approximately $41.5 million in gross profit. The company posted a GAAP net loss of $8.1 million, or -$0.19 per share, which missed analyst expectations of approximately -$0.11. On an adjusted basis, the loss per share was -$0.07.

Despite the GAAP loss, the company delivered adjusted EBITDA of $1.8 million, showing operational resilience. Results exclude the impact of previously divested businesses and certain one-time items.

AngioDynamics ended the quarter with $37.8 million in cash and zero debt, providing a stable financial foundation. Cash usage was approximately $3.0–3.1 million in the quarter, slightly better than internal expectations.

Following the results, management raised full-year fiscal 2026 guidance for the third consecutive quarter, citing continued momentum in Med Tech. The earnings call highlighted strategic progress, including clinical advancements and reimbursement tailwinds.